Marc Stefan Robillard

This inventor holds 16 USPTO granted patents and 13 published patent applications, plus 7 CIPO patents and 15 EPO patents. Top assignees: Tagworks Pharmaceuticals B.v., Koninklijke Philips Corporation N.v., Syncom B.v.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc Stefan Robillard. Retrieved from https://idiyas.com/inventor/marc-stefan-robillard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 7 (Patent Applications = 8)

EPO Patents = 15 (Patent Applications = 24)

Average Co-Inventor Count = 4.4

ph-index = 6

Forward Citations = 129(Granted Patents)

Company Filing History:

11 out of 11

Tagworks Pharmaceuticals B.v.

patents

5 out of 21,910

Koninklijke Philips Corporation N.v.

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735444 - Chemically cleavable group (2026-09-15),

2. 12714752 - COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY (2026-08-25),

3. 12653914 - Compounds for fast and efficient click release (2026-06-16),

4. 12186405 - Cleavable tetrazine used in bio-orthogonal drug activation (2025-01-07),

5. 11857636 - Bio-orthogonal drug activation (2024-01-02),

6. 11617799 - Cleavable tetrazine used in bio-orthogonal drug activation (2023-04-04),

7. 10967069 - Bio-orthogonal drug activation (2021-04-06),

8. 10927139 - Chemically cleavable group (2021-02-23),

9. 10376594 - Bio-orthogonal drug activation (2019-08-13),

10. 10004810 - Bio-orthogonal drug activation (2018-06-26),

11. 9931408 - Bio-orthogonal drug activation (2018-04-03),

12. 9913921 - Pretargeting kit for imaging or therapy comprising a trans-cyclooctene dienophile and a diene (2018-03-13),

13. 9463256 - Pretargeting kit, method and agents used therein (2016-10-11),

14. 9427482 - Agents for clearing biomolecules from circulation (2016-08-30),

15. 9421274 - Bio-orthogonal drug activation (2016-08-23),

Title: The Innovative Contributions of Marc Stefan Robillard

Introduction

Marc Stefan Robillard is a prominent inventor based in Eindhoven, Netherlands. He has made significant contributions to the field of bio-orthogonal drug activation, holding a total of 13 patents. His work focuses on advancements in chemical cleavage and targeted therapeutics, showcasing his expertise in innovative drug delivery systems.

Latest Patents

Robillard's latest patents include a cleavable tetrazine used in bio-orthogonal drug activation. This invention provides a method for chemically cleaving a construct by utilizing a diene as a cleavable group. The process involves the reaction of the diene with a dienophile, which undergoes an inverse electron demand Diels-Alder reaction. Additionally, he has developed a prodrug activation method that employs abiotic reactive chemical groups exhibiting bio-orthogonal reactivity. This method is particularly relevant for antibody-drug conjugates and targeted therapeutics.

Career Highlights

Throughout his career, Robillard has worked with notable companies such as Tagworks Pharmaceuticals B.V. and Koninklijke Philips Corporation N.V. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking innovations in the pharmaceutical industry.

Collaborations

Robillard has collaborated with esteemed colleagues, including Ronny Mathieu Versteegen and Wolter Ten Hoeve. These partnerships have further enhanced his research and development efforts in the field of drug activation and delivery.

Conclusion

Marc Stefan Robillard's contributions to the field of bio-orthogonal drug activation and his extensive patent portfolio highlight his role as a leading inventor. His innovative approaches continue to influence the development of targeted therapeutics and drug delivery systems.

Profile summary based on public USPTO records.